

The relationship of Adiponectin / Leptin ratio with metabolic syndrome

Kismat M. Turki*

BSc, PhD

Suma H. Mohammed**

BSc, MSc

Zina H. Abdul-Qahar*

FICMS (Chemical Pathology)

Summary:

Background: Metabolic syndrome is a cluster of risk factors for atherosclerotic cardiovascular disease caused by abdominal obesity, such as hyperglycemia, hypertension, dyslipidemia, and insulin resistance. Adiponectin is a protein hormone that modulates a number of metabolic processes, including glucose regulation and fatty acid catabolism. Adiponectin is exclusively secreted from adipose tissue into the bloodstream. Leptin, a hormone synthesized by fat tissue had been noted to regulate energy balance and metabolism. In this study investigated the relationships of adiponectin/leptin ratio with metabolic syndrome in apparently healthy Iraqi male adults.

Objective: This study was designed to investigate the relationship of adiponectin/leptin ratio with metabolic syndrome in apparently healthy Iraqi male adults.

Methods: Ninety male subjects were enrolled in study (mean age, 40.97 ± 7.94 years). Serum leptin level and adiponectin level were measured using an enzyme-linked immunosorbent assay. And the presence of metabolic syndrome was assessed.

Results: Mean leptin level was significantly higher (7.29 ± 0.38 ng/ml), while adiponectin and adiponectin/leptin ratio was significantly lower (4.78 ± 0.24 µg/ml; 0.74 ± 0.07) respectively in subjects with MS. With increasing number of metabolic syndrome components, the mean values of leptin increased and the adiponectin and adiponectin/leptin decreased.

Conclusion: adiponectin/leptin ratio correlated well with the presence and number of metabolic syndrome components in Iraqi male subjects.

Keywords: Adiponectin/leptin ratio; metabolic syndrome.

Introduction:

The metabolic syndrome (MS) is one of the leading public health issues around the world (1). The prevalence of MS is increasing in parallel with obesity and diabetes worldwide (2). Among the various criteria for the identification of MS, its major components are atherogenic dyslipidemia, insulin resistance, hypertension and abdominal obesity (3). MS is associated with an increased risk of coronary artery disease (CAD) and type 2 diabetes mellitus (DM). It is also known that abdominal obesity and insulin resistance play a central role in MS. (4) In recent years, attention has focused on the visceral adipose tissue due to the presence of many adipocytokines synthesized and released from adipocytes (5,6). It is known that visceral adipose tissue functions as a paracrine and an endocrine organ and secretes a number of adipocytokines which have either proinflammatory, atherogenic or protective effects including leptin, adiponectin, tumor necrosis factor- α (TNF- α), resistin, interleukin-6, and fatty acid binding protein 4 (7). Two adipocytokines, leptin and adiponectin, have been recognized as key regulators of various metabolic disorders (8). The ratio of adiponectin and leptin has also been reported

to be associated with insulin resistance, which is considered to be one of the pathophysiological conditions underlying MS (9).

Adiponectin is an adipocyte-derived hormone with antiatherogenic, antidiabetic and anti-inflammatory properties. It attenuates insulin resistance by increasing insulin sensitivity of the liver. In muscle, adiponectin enhances glucose utilization and fatty acid oxidation. In addition, adiponectin increases endothelial nitric oxide (NO) secretion and inhibits monocyte adhesion and smooth muscle cell proliferation in the vascular wall (10). Leptin is an anorexigenic hormone which is predominantly produced in adipose tissue (11). In addition to its effect on neuroendocrine, immune and reproductive systems, leptin regulates food intake, body weight and energy homeostasis (12). Increased adiposity was shown to be associated with hyperleptinemia which subsequently causes endothelial dysfunction, hypertension and cardiovascular diseases (13). In this study, we investigated the relationships of A/L ratio with cardiovascular risk factors, and the presence of metabolic syndrome in apparently healthy Iraqi male adults.

Materials and Methods:

Ninety apparently healthy, Iraqi middle aged men were recruited for the study during the period from 1st, December, 2010 to 1st, June, 2011. Subjects were classified into five groups:- Control group (n

* Department of Biochemistry, College of Medicine, University of Baghdad

**

=20). First group (n =20) :- (obese). Second group (n =20) :- (obese + (↑ TG or ↓ HDL)). Third group (n =20):- (obese +↑ TG + ↓ HDL). Fourth group (n =10):- (obese +↑ TG + ↓ HDL + hypertension). Serumleptinand adiponectin levels were measuredusing an enzyme-linked immunosorbent assay.The presence of metabolic syndrome was defined accordingto the American Heart Association/National Heart, Lung, andBlood Institute (AHA/NHLBI) diagnostic criteria (14).

Results:

The mean levels of leptin increased significantly ($P < 0.01$) while the A/Lratio andadiponectindecreased significantly ($P < 0.01$, $P < 0.01$) with an increasing number of MS components. As showed in table (1). The mean levels of leptin in subjects with MS were significantly higher than in those without MS (Table 2). In addition, subjects with MS ($n = 30$) showed a significantlylower A/L ratio compared with that of subjects without MS ($n=60$) values being (0.73 vs1.50; $p = 0.0001$).The mean level of adiponectin was significantlylower in subjects with MS compared with the subjects withoutMS(4.78vs7.05; $p = 0.0001$) (Table 2).

Table 1: (Mean ± SD) of, Adiponectin, Leptin and A/L ratio of the studied groups.

Variable	Groups					P-value
	Contro l n=20	G1 n=20	G2 n=20	G3 n=20	G4 n=10	
Adiponecti n μg/mL	7.85 ±1.59	7.25 ±0.8 6	6.04 ±1.3 5	5.40 ±1.0 3	3.52 ±0.9 3	<0.0 1 **
Leptine ng/mL	3.95 ±0.94	5.33 ±0.7 9	6.19 ±1.6 3	7.05 ±2.4 4	7.78 ±1.0 1	<0.0 1 **
A/ L ratio	2.06 ±0.48	1.39 ±0.2 8	1.05 ±0.4 1	0.88 ±0.3 8	0.45 ±0.1 1	<0.0 1 **

ANOVA: MS groups vs normal control.

** ($P < 0.01$), NS: not significant. A/L: adiponectin/leptin ratio.

Table 2: The comparison of mean adipokine levels, A/L ratios according to the presence or absence of metabolic syndrome components.

	Adiponectin μg/mL	Leptin ng/mL	A/L ratio
With MS n=30 (33.33%)	4.78 ± 0.24	7.29 ± 0.38	0.74 ± 0.07
Without MS n=60 (66.67%)	7.05 ± 0.19	5.16 ± 0.19	1.50 ± 0.07
P-value	0.0001**	0.0001**	0.0001**

**highly significant differences ($P < 0.0001$); A/L ratio: adiponectin/leptin ratio; MS: metabolic syndrome.

Discussion:

Metabolic syndrome (MS), a cluster of metabolic disorders such as obesity, hypertension, dyslipidemia, and hyperglyceridemia, increases the risk of developing atherosclerotic diseases such as cardiovascular disease (CVD) (15).In this study, A/L

ratio was significantly higher in those with MS compared with that in participants without MS which is in agreement with few studies performed in Asian participants (16). Obesity is characterized by hyperleptinemia andleptin levels decrease considerably during weight loss and are positively associated with body mass index (BMI) (17). Obesity is also characterized by hypoadiponectinemia, because adiponectin is inversely correlated with BMI (18). In MS patients, the levels of serum adiponectin are decreased (19).In a study performed with 2,046 Chinese adults,leptin/adiponectin (L/A) ratio showed a higher odds ratio inpatients with MS and a higher area under the curve in patientswith MS compared with those of adiponectin or leptin alone,suggesting the possibility thatL/A ratio can be a better diagnosticmarker for MS than leptin or adiponectin individually(20). In a study performed on 60 Korean adults with type 2 diabetes,participants with MS showed a lower A/L ratio comparedto those without MS(21).Also Yutaka, *et al.*, 2010 study disclosed factors associated with the increase in serum leptin and adiponectin, he mentioned that serum levels of leptin may be associated positively with MS, whereas adiponectin levels are associated negatively with MS and CAD, even in patients with various coronary risk factors(22).The present study results are in linewith the previous studies in that the presences of MS lead to decreasedA/L ratio.Interestingly, the A/L ratio was significantly higher in patients with metabolic syndrome compared with its counterpart. A/L ratio decreased as the number of metabolic syndrome components increased (23). So these data support the association of this novel ratio as the prediction marker for MS in Iraqi people.Leptin and adiponectin are individually known to be involved in the pathogenesis of obesity and MS (24, 25). Under such an obesity-related condition, the leptin levels are higher and adiponectin levels are lower, and thus, the A/L can be relatively low (8). This fact seems to explain the results obtained in the present study. These datasuggest that A/L ratio decreased in subjects with MS and graduallydecreased according to the number of MS components,suggesting A/L ratio as the predictive marker for MS in the Iraqi population. Further research is needed on the confirmationof A/L ratio as the marker for insulin resistance indexand MS in various ethnic groups before application to clinicalpractice.

References:

- Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome, 2005. *Lancet* 365: 1415-1428.
- Zimmet P, Alberti KG, Shaw J, 2001. Global and societal implications of the diabetes epidemic. *Nature* 414: 782-787.
- Alberti KGMM, Eckel RH, Grundy SM, *et al.*, 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and

- Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120: 1640-1645.
- Gami AS, Witt BJ, Howard DE, et al., 2007. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am CollCardiol* 49: 403-414.
- Maury E, Brichard SM, 2010. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. *Mol Cell Endocrinol* 314: 1-16.
- Galic S, Oakhill JS, Steinberg GR, 2010. Adipose tissue as an endocrine organ. *Mol Cell Endocrinol* 316: 129-139.
- 7- Iacobellis G, Pistilli D, Gucciardo M, et al, 2005. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. *Cytokine* 29: 251-255.
8. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentration in normal- weight and obese humans. *N Engl J Med* 1996; 334:292-5.
9. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. *Metabolism* 2005; 54:281-6.
10. Diez JJ, Iglesias P, 2003. The role of the novel adipocyte-derived hormone adiponectin in human disease. *Eur J Endocrinol* 148: 293- 300.
11. Ahima RS, Flier JS. Leptin, 2000. *Annu Rev Physiol* 62: 413-437.
12. Friedman JM, Halaas JL, 1998. Leptin and the regulation of body weight in mammals. *Nature* 395: 763-770.
13. Knudson JD, Payne GA, Borbouse L, Tune JD. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease, 2008. *Current Hypertension Reports* 10: 434-439.
14. Grundy SM, 2005. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. *ArteriosclerThrombVascBiol* 25:2243-4.
15. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabetes Care* 2005; 28:385-90.
16. Zhuo Q, Wang Z, Fu P, Piao J, Tian Y, Xu J, Yang X, 2009. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. *Diabetes Res Clin Pract* 84:27-33.
17. Anderlová K, et al. 2006. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. *Physiol Res.*; 55:277–83.
18. Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, and Itoh M. 2008. The ratio of leptin to adiponectin can be used as an index of insulin resistance. *Metabolism*; 57:268-73.
19. Alikashioglu E., Nazli G., Alev Ö., Yaşar Ş. and Nurgün K. 2009. The Relationship between Serum Adiponectin, Tumor Necrosis Factor-Alpha, Leptin Levels and Insulin Sensitivity in Childhood and Adolescent Obesity: Adiponectin is a Marker of Metabolic Syndrome. *J Clin Res Pediatr Endocrinol.* 1(5): 233–239.
20. Zhuo Q, Wang Z, Fu P, Piao J, Tian Y, Xu J, Yang X, 2009. Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. *Diabetes Res Clin Pract* 84:27-33.
21. Lee JM, Kim SR, Yoo SJ, Hong OK, Son HS, Chang SA, 2009. The relationship between adipokines, metabolic parameters and insulin resistance in patients with metabolic syndrome and type 2 diabetes. *J Int Med Res* 37:1803-12.
22. Yutaka Kajikawa, Masae Ikeda, Shunji Takemoto, Jun Tomoda, Natsuki Ohmaru and Shozo Kusachi. 2010 Association of Circulating Levels of Leptin and Adiponectin With Metabolic Syndrome and Coronary Heart Disease in Patients With Various Coronary Risk Factors, *International Heart Journal* . Vol. 52, No. 1 pp.17-22.
23. Seung-Hyun K. 2010. The Adiponectin/Leptin Ratio and Metabolic Syndrome in Healthy Korean Adult Males Korean. *Diabetes J.*; 34(4): 220 -221.
24. Beltowski J. Leptin and atherosclerosis. *Atherosclerosis* 2006;189: 47-60.
25. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. *Diabetes Obes Metab* 2007; 9:282-9.